← Leaderboards
David M. Ashley
Duke University
$7,073,119
Attributed
$7,843,537
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.6M · FY2017–25$10M$7.5M$5M$2.5M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,386,219 · 15
By mechanism
P01$7,573,441 · 1
U19$6,467,650 · 5
P50$4,734,011 · 4
R01$2,275,526 · 2
R33$1,540,837 · 1
R21$442,750 · 1
Top collaborators
- Jerry William Shay5 shared
- Francis Ali-Osman2 shared
- John H Sampson2 shared
- Matthias Gromeier1 shared
- Qijing Li1 shared
Most similar at Duke University
Same institution · by research overlap
- John H Sampson$43,413,436
- Matthias Gromeier$11,871,021
- Darell D Bigner$25,397,506
- David Reardon$8,732,934
- Yiping Yang$13,692,641
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsCollaborationsTumorInnovationMediatingResourcesReportingEnsureGlioblastomaUniversitiesPrimary Brain NeoplasmsBiological MarkersPre-ClinicalMalignant - DescriptorBrainImmunotherapeutic AgentBrain NeoplasmsGliomaPublishingOperative Surgical ProceduresTissuesImmunogenicMalignant Neoplasm Of BrainBiobank
Grant awards (35)
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration$836,369
U19 · FY2025 · CA · contact PI
ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas$766,065
R01 · FY2025 · CA · contact PI
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification$420,270
U19 · FY2025 · CA · contact PI
Administrative Core$101,519
U19 · FY2025 · CA · contact PI
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration$632,802
U19 · FY2024 · CA · contact PI
ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas$362,434
R01 · FY2024 · CA · contact PI
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification$257,935
U19 · FY2024 · CA · contact PI
Administrative Core$94,714
U19 · FY2024 · CA · contact PI
Neuro-Oncology Program$64,417
P30 · FY2024 · CA · contact PI
Duke SPORE in Brain Cancer$2,087,855
P50 · FY2023 · CA · contact PI
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration$586,523
U19 · FY2023 · CA · contact PI
ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas$376,962
R01 · FY2023 · CA · contact PI
Administrative Core$342,800
P50 · FY2023 · CA · contact PI
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification$328,761
U19 · FY2023 · CA · contact PI
Developmental Research Program$109,668
P50 · FY2023 · CA · contact PI
Administrative Core$89,827
U19 · FY2023 · CA · contact PI
Neuro-Oncology Program$72,653
P30 · FY2023 · CA · contact PI
Experimental Therapy for Brain Tumors$2,494,255
P01 · FY2022 · CA · contact PI
Duke SPORE in Brain Cancer$2,086,695
P50 · FY2022 · CA · contact PI
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration$843,249
U19 · FY2022 · CA · contact PI
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification$522,189
U19 · FY2022 · CA · contact PI
ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas$422,252
R01 · FY2022 · CA · contact PI
Administrative Core$123,529
U19 · FY2022 · CA · contact PI
Neuro-Oncology Program$72,653
P30 · FY2022 · CA · contact PI
Experimental Therapy for Brain Tumors$2,542,342
P01 · FY2021 · CA
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration$895,748
U19 · FY2021 · CA · contact PI
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification$606,672
U19 · FY2021 · CA · contact PI
Administrative Core$127,543
U19 · FY2021 · CA · contact PI
Neuro-Oncology Program$69,947
P30 · FY2021 · CA · contact PI
Experimental Therapy for Brain Tumors$2,536,844
P01 · FY2020 · CA
Neuro-Oncology Program$72,334
P30 · FY2020 · CA · contact PI
Is Low Tumor Mutational Burden Predictive of Response to Oncolytic Polio Virus Therapy in Recurrent Glioblastoma?$442,750
R21 · FY2019 · NS · contact PI
Role of GLUD2 as a metabolic driver of gliomas with IDH1 mutations$347,813
R01 · FY2019 · NS · contact PI
Career Development Program$106,993
P50 · FY2018 · CA · contact PI
Area A: Development of genetically tractable, driver gene-syngeneic brain tumor models for pre-clinical adoptive TCR-T therapy$1,540,837
R33 · FY2017 · CA